Fatal Methadone Toxicity: Potential Role of CYP3A4 Genetic Polymorphism (original) (raw)

Abstract

Methadone is difficult to administer as a therapeutic agent because of a wide range of interindividual pharmacokinetics, likely due to genetic variability of the CYP450 enzymes responsible for metabolism to its principal metabolite 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine (EDDP). CYP3A4 is one of the primary CYP450 isoforms responsible for the metabolism of methadone to EDDP in humans. The purpose of this study was to evaluate the role of CYP3A4 genetic polymorphisms in accidental methadone fatalities. A study cohort consisting of 136 methadone-only and 92 combined methadone/benzodiazepine fatalities was selected from cases investigated at the West Virginia and Kentucky Offices of the Chief Medical Examiner. Seven single nucleotide polymorphisms (SNPs) were genotyped within the CYP3A4 gene. Observed allelic and genotypic frequencies were compared with expected frequencies obtained from The National Center for Biotechnology Information dbSNP database. SNPs rs2242480 and rs2740574 demonstrated an apparent enrichment within the methadone-only overdose fatalities compared with the control group and the general population. This enrichment was not apparent in the methadone/benzodiazepine cases for these two SNPs. Our findings indicate that there may be two or more SNPs on the CYP3A4 gene that cause or contribute to the methadone poor metabolizer phenotype.

Loading...

Loading Preview

Sorry, preview is currently unavailable. You can download the paper by clicking the button above.

References (49)

  1. Hall, A.J., Logan, J.E., Toblin, R.L., Kaplan, J.A., Kraner, J.C., Bixler, D. et al. (2008) Patterns of abuse among unintentional pharmaceutical overdose fatalities. The Journal of the American Medical Association, 300, 2613-2620.
  2. Garrido, M.J., Troconiz, I.F. (1999) Methadone: a review of its pharmacokinetic/pharmacodynamic properties. Journal of Pharmacological and Toxicological Methods, 42, 61-66.
  3. Gouldin, W.M., Kennedy, D.T., Small, R.E. (2000) Methadone: history and recommendations for use in analgesia. American Pain Society Bulletin, 10, 5-6.
  4. Hendra, T.J., Gerrish, S.P., Forrest, A.R. (1996) Fatal methadone over- dose. British Medical Journal, 313, 481-482.
  5. Santiago, T.V., Edelman, N.H. (1985) Opioids and breathing. Journal of Applied Physiology, 59, 1675-1685.
  6. Wong, S.H., Wagner, M.A., Jentzen, J.M., Schur, C., Bjerke, J., Gock, S.B. et al. (2003) Pharmacogenomics as an aspect of molecular autopsy for forensic pathology/toxicology: does genotyping CYP 2D6 serve as an adjunct for certifying methadone toxicity? Journal of Forensic Sciences, 48, 1406-1415.
  7. Bertschy, G. (1995) Methadone maintenance treatment: an update. European Archives of Psychiatry and Clinical Neuroscience, 245, 114-124.
  8. Mitchell, T.B., Dyer, K.R., Newcombe, D., Salter, A., Somogyi, A.A., Bochner, F. et al. (2004) Subjective and physiological responses among racemic-methadone maintenance patients in relation to rela- tive (S)-vs. (R)-methadone exposure. British Journal of Clinical Pharmacology, 58, 609-617.
  9. Foster, D.J., Somogyi, A.A., Bochner, F. (1999) Methadone N-demethylation in human liver microsomes: lack of stereoselectivity and involvement of CYP3A4. British Journal of Clinical Pharmacology, 47, 403-412.
  10. Eap, C.B., Buclin, T., Baumann, P. (2002) Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence. Clinical Pharmacokinetics, 41, 1153-1193.
  11. Li, Y., Kantelip, J.P., Gerritsen-van Schieveen, P., Davani, S. (2008) Interindividual variability of methadone response: impact of genetic polymorphism. Molecular Diagnosis and Therapy, 12, 109 -124.
  12. Ferrari, A., Coccia, C.P., Bertolini, A., Sternieri, E. (2004) Methadone- metabolism, pharmacokinetics and interactions. Pharmacological Research, 50, 551-559.
  13. Boulton, D.W., Arnaud, P., DeVane, C.L. (2001) Pharmacokinetics and pharmacodynamics of methadone enantiomers after a single oral dose of racemate. Clinical Pharmacology and Therapeutics, 70, 48 -57.
  14. Leshner, A.I. (1997) Drug abuse and addiction treatment research: the next generation. Archives of General Psychiatry, 54, 691-694.
  15. Moody, D.E., Alburges, M.E., Parker, R.J., Collins, J.M., Strong, J.M. (1997) The involvement of cytochrome P450 3A4 in the N-demethylation of L-alpha-acetylmethadol (LAAM), norLAAM, and methadone. Drug Metabolism and Disposition, 25, 1347-1353.
  16. Nilsson, M.I., Anggard, E., Holmstrand, J., Gunne, L.M. (1982) Pharmacokinetics of methadone during maintenance treatment: adaptive changes during the induction phase. European Journal of Clinical Pharmacology, 22, 343-349.
  17. Iribarne, C., Berthou, F., Baird, S., Dreano, Y., Picart, D., Bail, J.P. et al. (1996) Involvement of cytochrome P450 3A4 enzyme in the N-demethylation of methadone in human liver microsomes. Chemical Research in Toxicology, 9, 365-373.
  18. Totah, R.A., Allen, K.E., Sheffels, P., Whittington, D., Kharasch, E.D. (2007) Enantiomeric metabolic interactions and stereoselective human methadone metabolism. Journal of Pharmacology and Experimental Therapeutics, 321, 389-399.
  19. Chang, Y., Fang, W.B., Lin, S.N., Moody, D.E. (2011) Stereo-selective metabolism of methadone by human liver microsomes and cDNA-expressed cytochrome P450s: a reconciliation. Basic & Clinical Pharmacology & Toxicology, 108, 55 -62.
  20. Eap, C.B., Broly, F., Mino, A., Hammig, R., Deglon, J.J., Uehlinger, C. et al. (2001) Cytochrome P450 2D6 genotype and methadone steady- state concentrations. Journal of Clinical Psychopharmacology, 21, 229-234.
  21. Eap, C.B., Crettol, S., Rougier, J.S., Schlapfer, J., Sintra Grilo, L., Deglon, J.J. et al. (2007) Stereoselective block of hERG channel by (S)-methadone and QT interval prolongation in CYP2B6 slow metab- olizers. Clinical Pharmacology and Therapeutics, 81, 719-728.
  22. Gerber, J.G., Rhodes, R.J., Gal, J. (2004) Stereoselective metabolism of methadone N-demethylation by cytochrome P4502B6 and 2C19. Chirality, 16, 36 -44.
  23. Shook, J.E., Watkins, W.D., Camporesi, E.M. (1990) Differential roles of opioid receptors in respiration, respiratory disease, and opiate-induced respiratory depression. The American Review of Respiratory Disease, 142, 895-909.
  24. White, J.M., Irvine, R.J. (1999) Mechanisms of fatal opioid overdose. Addiction, 94, 961-972.
  25. Shiran, M.R., Chowdry, J., Rostami-Hodjegan, A., Ellis, S.W., Lennard, M.S., Iqbal, M.Z. et al. (2003) A discordance between cytochrome P450 2D6 genotype and phenotype in patients undergoing metha- done maintenance treatment. British Journal of Clinical Pharmacology, 56, 220-224.
  26. Guengerich, F.P., Hosea, N.A., Parikh, A., Bell-Parikh, L.C., Johnson, W.W., Gillam, E.M. et al. (1998) Twenty years of bio- chemistry of human P450s: purification, expression, mechanism, and relevance to drugs. Drug Metabolism and Disposition, 26, 1175 -1178.
  27. Li, A.P., Kaminski, D.L., Rasmussen, A. (1995) Substrates of human he- patic cytochrome P450 3A4. Toxicology, 104, 1-8.
  28. Jin, M., Gock, S.B., Jannetto, P.J., Jentzen, J.M., Wong, S.H. (2005) Pharmacogenomics as molecular autopsy for forensic toxicology: genotyping cytochrome P450 3A4*1B and 3A5*3 for 25 fentanyl cases. Journal of Analytical Toxicology, 29, 590-598.
  29. Paine, M.F., Hart, H.L., Ludington, S.S., Haining, R.L., Rettie, A.E., Zeldin, D.C. (2006) The human intestinal cytochrome P450 "pie". Drug Metabolism and Disposition, 34, 880-886.
  30. Shimada, T., Yamazaki, H., Mimura, M., Inui, Y., Guengerich, F.P. (1994) Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. Journal of Pharmacology and Experimental Therapeutics, 270, 414-423.
  31. Westlind, A., Lofberg, L., Tindberg, N., Andersson, T.B., Ingelman-Sundberg, M. (1999) Interindividual differences in hepatic expression of CYP3A4: relationship to genetic polymorphism in the 5 0 -upstream regulatory region. Biochemical and Biophysical Research Communications, 259, 201-205.
  32. He, P., Court, M.H., Greenblatt, D.J., von Moltke, L.L. (2005) Genotype-phenotype associations of cytochrome P450 3A4 and 3A5 polymorphism with midazolam clearance in vivo. Clinical Pharmacology and Therapeutics, 77, 373-387.
  33. Ozdemir, V., Kalow, W., Tang, B.K., Paterson, A.D., Walker, S.E., Endrenyi, L. et al. (2000) Evaluation of the genetic component of variability in CYP3A4 activity: a repeated drug administration meth- od. Pharmacogenetics, 10, 373-388.
  34. Schmider, J., Greenblatt, D.J., von Moltke, L.L., Shader, R.I. (1996) Relationship of in vitro data on drug metabolism to in vivo pharma- cokinetics and drug interactions: implications for diazepam disposi- tion in humans. Journal of Clinical Psychopharmacology, 16, 267-272.
  35. Fonseca, F., de la Torre, R., Diaz, L., Pastor, A., Cuyas, E., Pizarro, N. et al. (2011) Contribution of cytochrome P450 and ABCB1 genetic variability on methadone pharmacokinetics, dose requirements, and response. PLoS One, 6, e19527.
  36. Crettol, S., Deglon, J.J., Besson, J., Croquette-Krokar, M., Hammig, R., Gothuey, I. et al. (2006) ABCB1 and cytochrome P450 genotypes and phenotypes: influence on methadone plasma levels and response to treatment. Clinical Pharmacology and Therapeutics, 80, 668-681.
  37. Evans, W.E., Relling, M.V. (1999) Pharmacogenomics: translating functional genomics into rational therapeutics. Science, 286, 487-491.
  38. Schirmer, M., Rosenberger, A., Klein, K., Kulle, B., Toliat, M.R., Nurnberg, P. et al. (2007) Sex-dependent genetic markers of CYP3A4 expression and activity in human liver microsomes. Pharmacogenomics, 8, 443-453.
  39. Sata, F., Sapone, A., Elizondo, G., Stocker, P., Miller, V.P., Zheng, W. et al. (2000) CYP3A4 allelic variants with amino acid substitutions in exons 7 and 12: evidence for an allelic variant with altered catalytic activity. Clinical Pharmacology and Therapeutics, 67, 48 -56.
  40. Dai, D., Tang, J., Rose, R., Hodgson, E., Bienstock, R.J., Mohrenweiser, H.W. et al. (2001) Identification of variants of CYP3A4 and character- ization of their abilities to metabolize testosterone and chlorpyrifos. Journal of Pharmacology and Experimental Therapeutics, 299, 825-831.
  41. Eiselt, R., Domanski, T.L., Zibat, A., Mueller, R., Presecan-Siedel, E., Hustert, E. et al. (2001) Identification and functional characterization of eight CYP3A4 protein variants. Pharmacogenetics, 11, 447-458.
  42. Garcia-Martin, E., Martinez, C., Pizarro, R.M., Garcia-Gamito, F.J., Gullsten, H., Raunio, H. (2002) CYP3A4 variant alleles in white indi- viduals with low CYP3A4 enzyme activity. Clinical Pharmacology and Therapeutics, 71, 196-204.
  43. Lamba, J.K., Lin, Y.S., Thummel, K., Daly, A., Watkins, P.B., Strom, S.J. (2002) Common allelic variants of cytochrome P4503A4 and their prevalence in different populations. Pharmacogenetics, 12, 121-132.
  44. van Schaik, R.H., de Wildt, S.N., Brosens, R., van Fessem, M., van den Anker, J.N., Lindemans, J. (2001) The CYP3A4*3 allele: is it really rare? Clinical Chemistry, 47, 1104-1106.
  45. Lamba, J.K., Lin, Y.S., Schuetz, E.G., Thummel, K.E. (2002) Genetic contribution to variable human CYP3A-mediated metabolism. Advanced Drug Delivery Reviews, 54, 1271-1294.
  46. Hirota, T., Ieiri, I., Takane, H., Maegawa, S., Hosokawa, M., Kobayashi, K. et al. (2004) Allelic expression imbalance of the human CYP3A4 gene and individual phenotypic status. Human Molecular Genetics, 13, 2959 -2969.
  47. Abraham, J., Earl, H.M., Pharoah, P.D., Caldas, C. (2006) Pharmacogenetics of cancer chemotherapy. Biochimic et Biophysica Acta, 1776, 168-183.
  48. Rodriguez-Antona, C., Sayi, J.G., Gustafsson, L.L., Bertilsson, L., Ingelman-Sundberg, M. (2005) Phenotype -genotype variability in the human CYP3A locus as assessed by the probe drug quinine and analyses of variant CYP3A4 alleles. Biochemical and Biophysical Research Communications, 338, 299-305.
  49. Wang, D., Guo, Y., Wrighton, S.A., Cooke, G.E., Sadee, W. (2011) Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs. Pharmacogenomics, 11, 274-286.